Nektar Therapeutics
Income Statement
| Line Item | Aug 2026 | Jun 2026 | May 2026 | Mar 2026 | Mar 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $10.1M | — | $10.9M | — | — | — | $11.8M |
| Cost of Revenue | — | — | — | — | — | — | — | $0 |
| Gross Profit | — | — | — | — | — | — | — | $11.8M |
| Gross Margin | — | — | — | — | — | — | — | 100.0% |
| Operating Expenses | ||||||||
| Research & Development | — | $39.1M | — | $35.7M | — | — | — | $27.3M |
| SG&A Expense | — | $12.8M | — | $13.4M | — | — | — | $16.1M |
| Operating Income | — | $-42.3M | — | $-39.1M | — | — | — | $-31.7M |
| Operating Margin | — | -417.9% | — | -359.6% | — | — | — | -268.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-40.3M | — | $-43.1M | — | — | — | $-35.0M |
| Income Tax Expense | — | $2.0K | — | $64.0K | — | — | — | $-33.0K |
| Net Income | — | $-40.6M | — | $-44.9M | — | — | — | $-35.5M |
| Net Margin | — | -401.0% | — | -413.4% | — | — | — | -301.3% |
| EPS (Basic) | — | $-1.23 | — | $-1.82 | — | — | — | $-1.87 |
| EPS (Diluted) | — | $-1.23 | — | $-1.82 | — | — | — | $-1.87 |
| Shares Outstanding (Basic) | 34.1M | 33.1M | 33.8M | 24.7M | 28.7M | 20.4M | 20.3M | 18.9M |
| Shares Outstanding (Diluted) | 34.1M | 33.1M | 33.8M | 24.7M | 28.7M | 20.4M | 20.3M | 18.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |